Introduction
Chronic myeloid leukemia (CML) accounts for approximately 15–20% of
all leukemias in adults1. CML is characterized by the
BCR-ABL1 fusion gene encoding a constitutively active tyrosine
kinase2. Tyrosine kinase inhibitor (TKI) can help to
increase the survival time in CML patients; however, the risk of
secondary malignancies due to TKIs is a growing concern. It is reported
that second malignancies developed in 3.1–4.5% of case during the
treatment course of CML, of which secondary lymphoma accounts for about
5%3-5. However, few reports showed clinical course of
patients who developed lymphoma during TKI therapies. Herein, we report
a case of high grade B-cell lymphoma (HGBCL) diagnosed in the course of
CML treatment with bosutinib and present the review of literature.